NEW You are able to–(BUSINESS WIRE)–Soterix
Medical, Corporation. announced today the PainX™
treatment platform in Canada for Fibromyalgia and Migraine according to
its proprietary transcranial Household Power Stimulation (tDCS)
technology. This announcement coincides using the receipt of Health
Canada approval to treat discomfort disorders in grown-ups.
Soterix Medical PainX™ tDCS Treatments are a non-invasive battery-powered
device that gives mild current to some region from the cerebral cortex to
either modulate response to painful encounters or control discomfort
perception. PainX™ tDCS is really a highly-promising therapy with no
systemic negative effects generally connected with dental discomfort medications.
In addition, it might present an invaluable choice for patients unresponsive
to traditional treatment.
"1 in 5 Canadian adults are afflicted by chronic discomfort. We’re glad
Soterix Medical can instruct this promising drug-free alternative," stated
Mr. Renato Moratore, VP Regulatory Matters for Soterix Medical. "The
Health Canada approval makes our unique tDCS technology to supply an
effective, safe and well-tolerated solution for chronic discomfort now
obtainable in Canada."
Mr. Kamran Nazim, Chief Product Manager of Soterix Medical explains,
"PainX™ system includes a little battery-powered stimulator that
connects to some headgear that painlessly guides current in the scalp to
intended brain regions. Soterix Medical team spent over 6 years testing
and validating this platform to engineer a effective and safe system."
The Canada approval is dependant on 16 positive studies spanning 10
years for conditions for example Fibromyalgia, Migraine, Spinal-cord Injuries,
etc. Generally, patients could experience rapid benefit. Some
studies demonstrated sustained benefit varying from three to 12 days
publish-stimulation. The most typical negative effects were restricted to itching
and tingling with rare cases of headache.
The immediate accessibility to PainX™ treatment in Canada provides
Canadian healthcare providers accessibility Soterix Treatment
Partnership Program. The program continues to be adopted effectively by over
100 centers within the Eu. With the Treatment Partnership
Program, Canadian medical clinics can immediately contact Soterix
Medical (at contact@soterixmedical.com)
for any comprehensive support package including specialized education,
on-site staff training, ongoing support, and treatment guidance.
CAUTION: tDCS is restricted by Federal (or U . s . States) law to
investigational only use.
Resourse: http://businesswire.com/news/home/20160928005675/en/
